Rapid Pruritus Reduction with Ruxolitinib Cream Treatment in Patients with Atopic Dermatitis

home / between-the-lines / rapid-pruritus-reduction-with-ruxolitinib-cream-treatment-in-patients-with-atopic-dermatitis

Dermatology experts review and discuss review the practical and clinical implications of the itch and pruritus data from the phase 3 TRuE-AD1 and TRuE-AD2 trials.

Overview of Atopic Dermatitis

EP. 1: Overview of Atopic Dermatitis

James Q. Del Rosso, DO;Raj Chovatiya, MD, PhD;Lisa Swanson, MD, FAAD
March 30th 2023

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, provide an overview of atopic dermatitis and review the burden of disease.

TRuE-AD1 and TRuE AD2 Trial Overview

EP. 2: TRuE-AD1 and TRuE AD2 Trial Overview

James Q. Del Rosso, DO;Raj Chovatiya, MD, PhD;Lisa Swanson, MD, FAAD
March 30th 2023

Dermatology experts review the design of the TRuE-AD1 and TRuE AD2 phase 3 trial.

TRuE-AD1 and TRuE AD2 Trial: Baseline Characteristics

EP. 3: TRuE-AD1 and TRuE AD2 Trial: Baseline Characteristics

James Q. Del Rosso, DO;Raj Chovatiya, MD, PhD;Lisa Swanson, MD, FAAD
April 6th 2023

Thought leaders provide an overview of the basline characteristics of the TRuE-AD1 and TRuE AD2 phase 3 trial.

Ruxolitinib Trial Results

EP. 4: Ruxolitinib Trial Results

James Q. Del Rosso, DO;Raj Chovatiya, MD, PhD;Lisa Swanson, MD, FAAD
April 6th 2023

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss the week 8 change results of ruxolitinib cream from the TRuE-AD1 and TRuE AD2 phase 3 trial.

TRuE-AD1 and TRuE AD2: Trial Data

EP. 5: TRuE-AD1 and TRuE AD2: Trial Data

James Q. Del Rosso, DO;Raj Chovatiya, MD, PhD;Lisa Swanson, MD, FAAD
April 13th 2023

James Q Del Rosso, DO, takes a closer look at the trial data regarding timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis.

Ruxolitinib: Clinical Context

EP. 6: Ruxolitinib: Clinical Context

James Q. Del Rosso, DO;Raj Chovatiya, MD, PhD;Lisa Swanson, MD, FAAD
April 13th 2023

Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss take a closer look at the TRuE-AD1 and TRuE AD2 phase 3 trial and provide context regarding ruxolitinib cream for the treatment of atopic dermatitis in the clinical setting.

TRuE-AD1 and TRuE-AD2 trials: Takeaway Points

EP. 7: TRuE-AD1 and TRuE-AD2 trials: Takeaway Points

James Q. Del Rosso, DO;Raj Chovatiya, MD, PhD;Lisa Swanson, MD, FAAD
April 13th 2023

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.

Ruxolitinib Offers Rapid Pruritus Reduction

EP. 8: Ruxolitinib Offers Rapid Pruritus Reduction

Emma Andrus, Assistant Editor
July 20th 2023

Clinicians James Q. Del Rosso, DO; Raj Chovatiya, MD, PhD; and Lisa Swanson, MD, PhD, review the study, “Rapid Pruritus Reduction With Ruxolitinib Cream in Patients With Atopic Dermatitis."

© 2024 MJH Life Sciences

All rights reserved.